Investor Relations

Overview

A Multi-Billion Dollar Oral Vaccine Platform

A kinder way to immunize against respiratory and enteric infectious diseases. QYNDR is the future vaccination technology.

Conduct and complete Phase II/III clinical development – COVID-19 vaccine
Produce cGMP quality product at pre-commercial scale
Prepare submissions for regulatory approvals
Advance additional vaccine candidates through IND and up to First-in-Humans Clinical Trials – Influenza, Group A Strep, Pertussis, RSV, others TBD

QYNDR: Use of Funds and Head Count Projections

Business Development & Sales

Governments purchase vaccines. Requires specialized government contracting and business development people.

Clinical Trial Execution & Global Regulatory Filings and Registrations

Contracting and managing contract research organizations (CRO) globally who conduct the clinical trial. This includes data collection, external analytical laboratory management, and regulatory filings.

CMO / Supply Chain Setup

Staff must develop and qualify supply chain with CMO to support clinical materials as they cannot be changed after application.

Clinical Materials Procurement

Staff trained and experienced with contract manufacturing will build processing lines capable of supporting clinical trials and full BLA approval for the oral vaccines.

Global Market: $41.4 Billion / CAGR 10.2%*

Global Vaccine Market projected to reach $149.2 billion by 2026 (Including COVID-19). The international community needs better vaccination platforms and more of them.
It is in the strategic interest of the United States to ensure that vaccines are available for citizens and visitors alike are. This oral platform is able to address global vaccination needs for respiratory and enteric infectious disease now and in the future.

Investor Relations